Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
作者信息
Aldoss Ibrahim, Yang Dongyun, Aribi Ahmed, Ali Haris, Sandhu Karamjeet, Al Malki Monzr M, Mei Matthew, Salhotra Amandeep, Khaled Samer, Nakamura Ryotaro, Snyder David, O'Donnell Margaret, Stein Anthony S, Forman Stephen J, Marcucci Guido, Pullarkat Vinod
机构信息
Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA.
Department of Information Sciences, Division of Biostatistics, City of Hope, Duarte, CA, USA.
出版信息
Haematologica. 2018 Sep;103(9):e404-e407. doi: 10.3324/haematol.2018.188094. Epub 2018 Mar 15.
Abstract
摘要
相似文献
1
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.维奈克拉与去甲基化药物联合治疗复发/难治性急性髓系白血病的疗效
Haematologica. 2018 Sep;103(9):e404-e407. doi: 10.3324/haematol.2018.188094. Epub 2018 Mar 15.
2
Hypomethylating agents and venetoclax in acute myeloid leukemia.急性髓系白血病中的去甲基化药物与维奈克拉
Clin Adv Hematol Oncol. 2021 Feb;19(2):82-83.
3
Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.克拉屈滨加阿糖胞苷加维奈克拉治疗对维奈克拉加去甲基化药物难治或复发的急性髓系白血病
Haematologica. 2024 Aug 1;109(8):2706-2710. doi: 10.3324/haematol.2024.284962.
4
The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies.维奈托克和地西他滨用于治疗相关急性髓系白血病合并晚期非血液系统恶性肿瘤的可行性。
Leuk Res. 2019 Sep;84:106196. doi: 10.1016/j.leukres.2019.106196. Epub 2019 Jul 30.
5
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.10天阿扎胞苷联合维奈克拉用于新诊断的不适合强化化疗以及复发或难治性急性髓系白血病的治疗：一项单中心2期试验
Lancet Haematol. 2020 Oct;7(10):e724-e736. doi: 10.1016/S2352-3026(20)30210-6. Epub 2020 Sep 5.
6
Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.维奈托克联合地西他滨可诱导造血干细胞移植后复发的急性髓系白血病完全缓解并伴有分子学反应。
Am J Hematol. 2019 Feb;94(2):E48-E50. doi: 10.1002/ajh.25352. Epub 2018 Nov 29.
7
Venetoclax with decitabine or azacitidine for AML.维奈托克联合地西他滨或阿扎胞苷治疗急性髓系白血病
Lancet Oncol. 2018 Dec;19(12):e672. doi: 10.1016/S1470-2045(18)30824-6. Epub 2018 Nov 1.
8
Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.维奈托克联合疗法治疗复发/难治性急性髓系白血病：单机构经验
Leuk Res. 2020 Mar;90:106314. doi: 10.1016/j.leukres.2020.106314. Epub 2020 Jan 30.
9
RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia.RUNX1突变与复发/难治性急性髓系白血病对维奈克拉联合疗法的反应相关。
Leuk Res. 2021 Dec;111:106735. doi: 10.1016/j.leukres.2021.106735. Epub 2021 Oct 23.
10
Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.白血病遗传学与复发/难治性急性髓系白血病对维奈托克和去甲基化药物反应的关联
Am J Hematol. 2019 Oct;94(10):E253-E255. doi: 10.1002/ajh.25567. Epub 2019 Jul 10.
引用本文的文献
1
Repurposing the Antidepressant Sertraline: A Systematic Scoping Review of Its Anticancer Mechanisms.重新利用抗抑郁药舍曲林：对其抗癌机制的系统综述。
Pharmacol Res Perspect. 2025 Oct;13(5):e70168. doi: 10.1002/prp2.70168.
2
Durable response to venetoclax, azacytidine, and ruxolitinib in chronic-phase myelofibrosis resistant to ruxolitinib: a case report and literature review.鲁索替尼耐药的慢性期骨髓纤维化患者对维奈克拉、阿扎胞苷和鲁索替尼的持久反应：一例报告及文献综述
Front Oncol. 2025 Aug 8;15:1644661. doi: 10.3389/fonc.2025.1644661. eCollection 2025.
3
The Impact of the COVID-19 Pandemic on an Immunocompromised Patient with Allogeneic Haematopoietic Stem Cell Transplant: A Dual Perspective from Patient and Physician Standpoints.2019年冠状病毒病大流行对异基因造血干细胞移植免疫功能低下患者的影响：患者和医生双视角
Oncol Ther. 2025 Aug 25. doi: 10.1007/s40487-025-00364-0.
4
Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML.口服酪蛋白激酶1α和细胞周期蛋白依赖性激酶7/9抑制剂BTX A51用于晚期骨髓增生异常综合征和急性髓系白血病的I期首次人体剂量递增研究。
J Hematol Oncol. 2025 Jul 15;18(1):73. doi: 10.1186/s13045-025-01724-z.
5
Efficacy and prognostic analysis of venetoclax combined with hypomethylating agents for induction therapy in acute myeloid leukemia: a multi-center real-world study on indication-specific stratification, molecular markers, and hematologic toxicities.维奈托克联合去甲基化药物用于急性髓系白血病诱导治疗的疗效及预后分析：一项关于适应证特异性分层、分子标志物和血液学毒性的多中心真实世界研究
Cancer Cell Int. 2025 Jul 1;25(1):241. doi: 10.1186/s12935-025-03858-z.
6
Venetoclax synergizes with Wnt/β-catenin inhibitor C-82 in acute myeloid leukemia by increasing the degradation of Mcl-1 protein.维奈托克通过增加Mcl-1蛋白的降解，与Wnt/β-连环蛋白抑制剂C-82在急性髓系白血病中发挥协同作用。
Cancer Cell Int. 2025 May 29;25(1):197. doi: 10.1186/s12935-025-03825-8.
7
Development of a clinical prediction model for sensitivity to combination therapy of Bcl-2 inhibitors and hypomethylating agents in elderly/unfit patients with acute myeloid leukemia.老年/不适合进行强化疗的急性髓系白血病患者对Bcl-2抑制剂与低甲基化药物联合治疗敏感性的临床预测模型的开发。
Discov Oncol. 2025 May 20;16(1):831. doi: 10.1007/s12672-025-02612-1.
8
IFN-γ and donor leukocyte infusions for relapsed myeloblastic malignancies after allogeneic hematopoietic stem cell transplantation.干扰素-γ与供体白细胞输注用于异基因造血干细胞移植后复发的髓母细胞性恶性肿瘤
JCI Insight. 2025 Mar 25;10(9). doi: 10.1172/jci.insight.190655. eCollection 2025 May 8.
9
Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations.携带TP53突变的髓系肿瘤异基因移植后生存相关因素。
Blood Adv. 2025 Mar 14. doi: 10.1182/bloodadvances.2024015335.
10
Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy.维奈托克联合去甲基化药物治疗复发/难治性急性髓系白血病患者反应和生存的分子预测指标
Haematologica. 2025 Aug 1;110(8):1865-1869. doi: 10.3324/haematol.2024.286991. Epub 2025 Feb 27.
本文引用的文献
1
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.维奈托克联合地西他滨或阿扎胞苷治疗初治老年急性髓系白血病患者。
Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25.
2
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Venetoclax 作为靶向治疗复发/难治性 t(11;14)多发性骨髓瘤的疗效。
Blood. 2017 Nov 30;130(22):2401-2409. doi: 10.1182/blood-2017-06-788786. Epub 2017 Oct 10.
3
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.成人急性髓系白血病的诊断与管理：2017年国际专家小组的欧洲白血病网络（ELN）建议
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.
4
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.维奈托克单药治疗急性髓性白血病患者的II期研究中的疗效及反应的生物学关联
Cancer Discov. 2016 Oct;6(10):1106-1117. doi: 10.1158/2159-8290.CD-16-0313. Epub 2016 Aug 12.
5
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.在复发的慢性淋巴细胞白血病中使用维奈托克靶向BCL2
N Engl J Med. 2016 Jan 28;374(4):311-22. doi: 10.1056/NEJMoa1513257. Epub 2015 Dec 6.
6
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.阿扎胞苷对比传统治疗方案用于新诊断的原始细胞比例>30%的老年急性髓系白血病患者的国际3期研究。
Blood. 2015 Jul 16;126(3):291-9. doi: 10.1182/blood-2015-01-621664. Epub 2015 May 18.
7
Azacitidine for the treatment of relapsed and refractory AML in older patients.阿扎胞苷治疗老年复发/难治性 AML。
Leuk Res. 2015 Feb;39(2):124-30. doi: 10.1016/j.leukres.2014.11.009. Epub 2014 Nov 24.
8
BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.BCL-2 家族蛋白作为 5-氮杂胞苷增敏靶点及髓系恶性肿瘤反应的决定因素。
Leukemia. 2014 Aug;28(8):1657-65. doi: 10.1038/leu.2014.44. Epub 2014 Jan 23.
9
BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.BCL-2 抑制作用靶向氧化磷酸化并选择性根除静止期人类白血病干细胞。
Cell Stem Cell. 2013 Mar 7;12(3):329-41. doi: 10.1016/j.stem.2012.12.013. Epub 2013 Jan 17.
10
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.阿扎胞苷相较于传统治疗方案可延长低骨髓原始细胞计数的老年急性髓系白血病患者的总生存期。
J Clin Oncol. 2010 Feb 1;28(4):562-9. doi: 10.1200/JCO.2009.23.8329. Epub 2009 Dec 21.
Zotero 插件